Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study

Influenza Other Respir Viruses. 2024 Apr;18(4):e13292. doi: 10.1111/irv.13292.

Abstract

Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October-November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58-74) and 67% (95%CI: 42-81) in 65- to 79-year-olds and 66% (95%CI: 57-73) and 72% (95%CI: 51-85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.

Keywords: COVID‐19; SARS‐CoV‐2; cohort design; electronic health records; hospitalisation; multicountry study; vaccine effectiveness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19 Vaccines* / immunology
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Electronic Health Records
  • Europe / epidemiology
  • European Union*
  • Female
  • Hospitalization* / statistics & numerical data
  • Humans
  • Male
  • Retrospective Studies
  • SARS-CoV-2* / immunology
  • Vaccination / statistics & numerical data
  • Vaccine Efficacy*

Substances

  • COVID-19 Vaccines